See more : Mutares SE & Co. KGaA (MUX.DE) Income Statement Analysis – Financial Results
Complete financial analysis of ClearPoint Neuro, Inc. (CLPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ClearPoint Neuro, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Jason Furniture (Hangzhou) Co.,Ltd. (603816.SS) Income Statement Analysis – Financial Results
- Hamilton Thorne Ltd. (HTLZF) Income Statement Analysis – Financial Results
- US Copper Corp. (USCUF) Income Statement Analysis – Financial Results
- RocketFuel Blockchain, Inc. (RKFL) Income Statement Analysis – Financial Results
- Salasar Techno Engineering Limited (SALASAR.NS) Income Statement Analysis – Financial Results
ClearPoint Neuro, Inc. (CLPT)
About ClearPoint Neuro, Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.96M | 20.55M | 16.30M | 12.83M | 11.22M | 7.35M | 7.38M | 5.75M | 4.59M | 3.60M | 3.93M | 5.06M | 3.82M | 2.67M |
| Cost of Revenue | 10.34M | 7.02M | 5.01M | 3.71M | 3.83M | 2.43M | 2.90M | 2.64M | 1.99M | 1.93M | 1.42M | 555.70K | 656.41K | 16.31K |
| Gross Profit | 13.61M | 13.53M | 11.29M | 9.12M | 7.38M | 4.92M | 4.48M | 3.11M | 2.61M | 1.68M | 2.51M | 4.50M | 3.16M | 2.65M |
| Gross Profit Ratio | 56.83% | 65.84% | 69.27% | 71.09% | 65.83% | 66.91% | 60.72% | 54.03% | 56.74% | 46.53% | 63.84% | 89.01% | 82.81% | 99.39% |
| Research & Development | 11.71M | 10.89M | 8.99M | 4.69M | 2.92M | 2.31M | 2.81M | 2.63M | 1.96M | 3.30M | 2.92M | 1.60M | 4.25M | 5.68M |
| General & Administrative | 11.76M | 9.61M | 8.76M | 5.27M | 4.30M | 4.33M | 4.05M | 4.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 12.60M | 9.36M | 6.92M | 5.38M | 4.76M | 3.53M | 3.96M | 3.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 24.35M | 18.97M | 15.68M | 10.65M | 9.06M | 7.86M | 8.00M | 7.97M | 8.37M | 8.04M | 7.06M | 6.03M | 4.83M | 4.70M |
| Other Expenses | 0.00 | -22.00K | -63.00K | 882.00K | 9.05K | 364.00 | 16.68K | 216.08K | 230.88K | 1.80M | 863.79K | 2.80K | 104.85K | 413.62K |
| Operating Expenses | 36.06M | 29.86M | 24.67M | 15.34M | 11.98M | 10.17M | 10.82M | 10.60M | 10.33M | 11.34M | 9.98M | 7.63M | 9.08M | 10.38M |
| Cost & Expenses | 46.40M | 36.88M | 29.67M | 19.05M | 15.81M | 12.60M | 13.72M | 13.24M | 12.32M | 13.26M | 11.41M | 8.19M | 9.74M | 10.40M |
| Interest Income | 386.00K | 81.00K | 973.00K | 1.44M | 955.00K | 0.00 | 0.00 | 8.81K | 16.46K | 11.62K | 24.54K | 14.15K | 3.48K | 10.40K |
| Interest Expense | 0.00 | 81.00K | 973.00K | 1.44M | 955.17K | 980.38K | 872.93K | 1.06M | 1.26M | 1.01M | 475.30K | 2.58M | 2.50M | 1.59M |
| Depreciation & Amortization | 1.46M | 777.00K | 692.00K | 550.00K | 250.56K | 109.44K | 116.45K | 155.71K | 211.95K | 377.26K | 426.18K | 416.97K | 354.89K | 266.22K |
| EBITDA | -20.99M | -15.58M | -12.75M | -4.79M | -4.33M | -5.07M | -6.18M | -6.85M | -6.97M | -3.13M | -6.16M | -2.70M | -5.46M | -7.60M |
| EBITDA Ratio | -87.62% | -75.80% | -78.19% | -37.30% | -38.64% | -69.87% | -84.05% | -123.63% | -158.07% | -217.95% | -168.19% | -61.81% | -145.70% | -279.09% |
| Operating Income | -22.45M | -16.33M | -13.37M | -6.22M | -4.59M | -5.25M | -6.34M | -7.49M | -8.97M | -5.32M | -7.47M | -3.13M | -5.92M | -9.52M |
| Operating Income Ratio | -93.70% | -79.47% | -82.05% | -48.48% | -40.95% | -71.37% | -85.86% | -130.25% | -195.34% | -147.61% | -190.17% | -61.87% | -155.09% | -356.45% |
| Total Other Income/Expenses | 357.00K | -103.00K | -1.04M | -562.00K | -945.79K | -915.70K | -831.52K | -581.16K | 524.86K | 795.89K | 388.50K | -2.58M | -2.39M | 61.06K |
| Income Before Tax | -22.09M | -16.44M | -14.41M | -6.78M | -5.54M | -6.16M | -7.17M | -8.07M | -8.45M | -4.52M | -7.09M | -5.71M | -8.31M | -9.45M |
| Income Before Tax Ratio | -92.21% | -79.97% | -88.41% | -52.86% | -49.39% | -83.82% | -97.12% | -140.36% | -183.91% | -125.53% | -180.29% | -112.83% | -217.68% | -354.16% |
| Income Tax Expense | 0.00 | 103.00K | 910.00K | 2.33M | 964.22K | 64.68K | 889.61K | 1.28M | 1.49M | 2.43M | 912.90K | 2.17M | 2.50M | 1.59M |
| Net Income | -22.09M | -16.54M | -15.32M | -9.11M | -6.50M | -6.16M | -7.17M | -8.07M | -8.45M | -4.52M | -7.09M | -5.71M | -8.31M | -9.45M |
| Net Income Ratio | -92.21% | -80.47% | -93.99% | -71.00% | -57.98% | -83.82% | -97.12% | -140.36% | -183.91% | -125.53% | -180.29% | -112.83% | -217.68% | -354.16% |
| EPS | -0.90 | -0.68 | -0.74 | -0.57 | -0.49 | -0.56 | -0.93 | -2.93 | -4.48 | -3.06 | -4.95 | -5.65 | -20.73 | -23.76 |
| EPS Diluted | -0.90 | -0.68 | -0.74 | -0.57 | -0.49 | -0.56 | -0.93 | -2.93 | -4.48 | -3.06 | -4.95 | -5.65 | -20.73 | -23.76 |
| Weighted Avg Shares Out | 24.61M | 24.18M | 20.73M | 15.85M | 13.16M | 10.93M | 7.74M | 2.75M | 1.88M | 1.48M | 1.43M | 1.01M | 401.03K | 397.98K |
| Weighted Avg Shares Out (Dil) | 24.61M | 24.18M | 20.73M | 15.85M | 13.16M | 10.93M | 7.74M | 2.75M | 1.88M | 1.48M | 1.43M | 1.01M | 401.03K | 397.98K |
ClearPoint Neuro to Present at Upcoming Investor Conferences
SOLANA BEACH, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the following investor conferences:
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 21.05% and 6.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Q3 2022 Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants William Wood - B. Riley Frank Takkinen - Lake Street Capital...
ClearPoint Neuro: Continuous Great Execution
Revenue growth rebounded strongly due to its acceleration in B&DD and capital equipment and software revenue. The company marks its first milestone with its FDA approval with PTC-AADC, with certainly more to come.
2 Stocks Under $20 to Watch
Here are two interesting companies under $20.
ClearPoint Neuro: Picks & Shovels Galore
Shares have lost 20% of their value since the initial public offering in February of last year. The company is well-positioned as a "picks and shovels" play to pharmaceutical partners addressing neurological indications.
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 0% and 0.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) CEO Joe Burnett on Q2 2022 Results - Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Joe Burnett - Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital William...
ClearPoint Neuro: A 'Picks And Shovels' Biotech Company
CLPT has been growing revenues steadily and has a large addressable market. It also has a very strong moat due to the nature of the FDA approval process.
ClearPoint Neuro, Inc. (CLPT) Surges 7.6%: Is This an Indication of Further Gains?
ClearPoint Neuro, Inc. (CLPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Source: https://incomestatements.info
Category: Stock Reports